Novartis Ag

Shanghai Aucta Pharmaceuticals Co., Ltd.

Emisphere Technologies, Inc.

Spero Therapeutics, Inc.

Nordic Bioscience A/s

Novartis Pharma Gmbh

Shoufeng Li

Moise Azria

Simon David Bateman

Shaoqiong Lyu

Alan Edward Royce

Anasuya Ashok Ghosh

Zhongqin Wang

Akash Jain

Zhihui Qiu

Xun Zheng

Claus Christiansen

Enxian Lu

Ping Li

Burkhard Schlütermann

Zhao Yi

Ye Huang

Catherine Curdy

Mangesh Sadashiv Bordawekar

Dieter Becker

Yi Zhao

Qiaolin Ren

Luke Utley

Timothy Keutzer

Joyce Macwan

Frédéric Gerber

Upkar Bhardwaj

Grazyna Fraczkiewicz

Alexey Makarov

Fen Ren

Ann Reese Comfort

Bolun Zhang

Daniel Eliot Benjamin

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.

Formulation for lacosamide

Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Tebipenem pivoxil immediate and modified release oral dosage forms

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Lacosamide pharmaceutical composition and dosage form thereof

A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.

Topical formulations containing mTOR inhibitors

This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

Powder for oral suspension containing lamotrigine

The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

Pharmaceutical composition

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.

Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation

The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.

Use of calcitonin in osteoarthritis

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Method for treating bone related diseases and calcium disorders

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Growing community of inventors

Basking Ridge, NJ, United States of America

Shoufeng Li